Trevi Therapeutics

Yahoo Finance • 9 days ago

Trevi Therapeutics to Participate in Upcoming Events

NEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic co... Full story

Yahoo Finance • 18 days ago

As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?

On February 17, 2026, Acorn Capital Advisors reported selling 225,000 shares of Terns Pharmaceuticals(NASDAQ:TERN), an estimated $5.20 million trade based on quarterly average pricing. What happened According to a filing with the Securit... Full story

Yahoo Finance • 24 days ago

After-Hours Earnings Report for March 17, 2026 : LULU, DOCU, OKLO, HQY, NN, QFIN, TRVI, CLPT, CBUS, OPTT, STRR, SDST

The following companies are expected to report earnings after hours on 03/17/2026. Visit our Earnings Calendar for a full list of expected earnings releases. lululemon athletica inc. (LULU)is reporting for the quarter ending January 31... Full story

Yahoo Finance • 4 months ago

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones

Key Points Boston-based MPM BioImpact sold 1.3 million shares of MBX Biosciences worth an estimated $14.8 million in the third quarter. The move marked a full exit for MPM BioImpact, which reported holding no shares of MBX at the end of t... Full story

Yahoo Finance • 5 months ago

Trevi Therapeutics targets multiple phase III trial launches for chronic cough indications in 2026 as regulatory plans accelerate

Earnings Call Insights: Trevi Therapeutics (TRVI) Q3 2025 MANAGEMENT VIEW * Jennifer Good, Co-Founder, CEO, President, and Interim Principal Financial Officer, highlighted, "The first half of this year was a major inflection point for... Full story

Yahoo Finance • 7 months ago

Haduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan Stanley

Trevi Therapeutics Inc. (NASDAQ:TRVI) is one of the best multibagger stocks to invest in right now. On August 21, Morgan Stanley’s Judah Frommer initiated coverage of the stock with an Overweight rating and an $18 price target. The Overwei... Full story

Yahoo Finance • 7 months ago

Trevi spikes as B. Riley reportedly cites deal prospects

[Wall street] Trevi Therapeutics (NASDAQ:TRVI [https://seekingalpha.com/symbol/TRVI]), a clinical-stage biopharma focused on treatments for cough conditions, traded higher on Wednesday after B. Riley, with a Buy rating, reportedly highlig... Full story

Yahoo Finance • 8 months ago

CoreWeave upgraded, Instacart downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Morgan Stanley upgraded HP Enterprise(... Full story

Yahoo Finance • 8 months ago

Trevi Therapeutics outlines $204M cash runway into 2029 as Phase III programs advance following positive CORAL data

Earnings Call Insights: Trevi Therapeutics (TRVI) Q2 2025 MANAGEMENT VIEW * Jennifer L. Good, CEO, described the first half of the year as a major inflection point for Trevi, highlighting positive data from the CORAL trial in idiopathi... Full story

Yahoo Finance • 9 months ago

TRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Trevi Therapeutics, Inc. (NASDAQ: TRVI) and Encourages Long-Term Investors to Contact the Firm 

PHILADELPHIA, June 26, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Trevi Therapeutics, Inc. (NASDAQ: TRVI) (“Trevi”) on behalf of the company’s long-term investors. Click here for additional information:... Full story

Yahoo Finance • 10 months ago

Trevi Therapeutics prices $100M stock at $5.75 per share

* Clinical-stage biopharmaceutical company Trevi Therapeutics (NASDAQ:TRVI [https://seekingalpha.com/symbol/TRVI]) priced [https://seekingalpha.com/pr/20125587-trevi-therapeutics-announces-pricing-of-100-million-underwritten-offering-... Full story

Yahoo Finance • 10 months ago

Trevi Therapeutics announces public offering of common stock

* Trevi Therapeutics (NASDAQ:TRVI [https://seekingalpha.com/symbol/TRVI]) announced on Monday that it has commenced an underwritten public offering of $100 million of shares of its common stock.  * In addition, Trevi expects to grant t... Full story

Yahoo Finance • 3 years ago

Presenting on the Emerging Growth Conference on February 22 Register Now

MIAMI, Feb. 21, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 50th Emerging Growth Conference on February 22, 2023. The Emerging Growth Conference identifies compa... Full story

Yahoo Finance • 3 years ago

Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors

Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors Brings 30 years of experience building private and public development-stage and commercial biopharmaceutical companies and has overseen severalsuccessful IPOs and trade... Full story

Yahoo Finance • 4 years ago

These 2 Penny Stocks Have Over 300% Upside on the Horizon, Says Oppenheimer

Earlier this month, the S&P 500 officially entered a bear market; its current year-to-date loss stands at 21%, and the NASDAQ, which has fallen faster and farther, stands at a 30% ytd loss. The rapid reversal not only put the bulls back in... Full story